← Back to Search

ASL-MRI for Glioblastoma Treatment Assessment

N/A

Recruiting

Led By Ananth Madhuranthakam, PhD

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Scheduled to undergo chemoradiation

Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

Study Summary

This trial will use MRI to study how well a treatment for glioblastoma works.

Who is the study for?

This trial is for patients with newly diagnosed Glioblastoma (GBM) who haven't started treatment. They must be in good enough health to perform daily activities, not have severe allergies to MRI contrast agents, and women must not be pregnant. It's also important that participants don't have any metal devices or conditions that make MRI unsafe.Check my eligibility

What is being tested?

The study tests how well a special type of MRI scan called Arterial Spin Labeling (ASL) can track the effectiveness of GBM treatments over time. Participants will undergo seven additional ASL-MRI scans before, during, and after their standard therapy to monitor changes in brain perfusion.See study design

What are the potential side effects?

MRI with ASL is generally safe but may cause discomfort due to the length of time spent in the scanner. There's a small risk of allergic reaction to gadolinium if used, though this trial avoids it. Claustrophobia or back pain could worsen due to lying still during scanning.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am scheduled for combined chemotherapy and radiation treatment.

Select...

I am able to care for myself and perform daily activities.

Select...

I have been diagnosed with glioblastoma multiforme (GBM).

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in perfusion within enhancing tumor

Progression Free Survival (PFS)

Secondary outcome measures

ASL measured perfusion within enhancing tumor

Overall Survival (OS)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Glioblastoma PatientsExperimental Treatment1 Intervention

Patients with histologically proven glioblastoma will undergo enhanced MRI with arterial spin labeling at weeks 0, 3, 6, 10, 18, 26, and 34 after beginning standard of care treatment.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,048 Previous Clinical Trials

1,053,695 Total Patients Enrolled

2 Trials studying Glioblastoma

30 Patients Enrolled for Glioblastoma

Ananth Madhuranthakam, PhDPrincipal Investigator - UT Southwestern Medical Center

University of Texas Southwestern Medical Center

1 Previous Clinical Trials

40 Total Patients Enrolled

Media Library

MRI with Arterial Spin Labeling (ASL) Clinical Trial Eligibility Overview. Trial Name: NCT03922984 — N/A

Glioblastoma Research Study Groups: Glioblastoma Patients

Glioblastoma Clinical Trial 2023: MRI with Arterial Spin Labeling (ASL) Highlights & Side Effects. Trial Name: NCT03922984 — N/A

MRI with Arterial Spin Labeling (ASL) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03922984 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new enrollees still being sought for this experiment?

"According to the public clinicaltrials.gov database, this clinical trial is currently recruiting patients. The listing was first posted on April 16th, 2019 and was last updated on October 6th, 2020."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma

Ananth Madhuranthakam 2019. "Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03922984.

All > Glioblastoma Dallas > Glioblastoma Multiforme